# A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

> **NCT00074854** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 87 (—)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** CP-547,632

## Key facts

- **NCT ID:** NCT00074854
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 87 (—)
- **Last updated:** 2006-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074854, "A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00074854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*